Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 143

Results For "bio"

4177 News Found

Lupin receives USFDA nod for Famotidine injection
Drug Approval | May 15, 2026

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market


Telangana life sciences ecosystem reaches $145 billion valuation
Biotech | May 15, 2026

Telangana life sciences ecosystem reaches $145 billion valuation

The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters


OneSource records Rs. 4,282 million revenue in Q4 FY26
News | May 15, 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold


Merck to showcase 100+ oncology studies at 2026 ASCO meeting
R&D | May 14, 2026

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline


Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
News | May 14, 2026

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros


Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
News | May 14, 2026

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion


Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
Clinical Trials | May 14, 2026

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies


Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis
R&D | May 13, 2026

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline